These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 37013524)

  • 21. Comparing mortality from covid-19 to mortality due to overdose: A micromort analysis.
    Lee Y; Lui LMW; Brietzke E; Liao Y; Lu C; Ho R; Subramaniapillai M; Mansur RB; Rosenblat JD; McIntyre RS
    J Affect Disord; 2022 Jan; 296():514-521. PubMed ID: 34656039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A qualitative study on perceptions and experiences of overdose among people who smoke drugs in Vancouver, British Columbia.
    Ivsins A; Bonn M; McNeil R; Boyd J; Kerr T
    Drug Alcohol Depend; 2024 May; 258():111275. PubMed ID: 38581922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating opioid preference to inform safe supply services: A cross sectional study.
    Ferguson M; Parmar A; Papamihali K; Weng A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Mar; 101():103574. PubMed ID: 35007878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "It gets you high as a kite but not unsick": Characterizations of and responses to a changing local drug supply by people who use drugs in Rhode Island.
    Collins AB; Macon EC; Levin S; Wunsch C; Wightman RS
    Int J Drug Policy; 2024 May; 127():104391. PubMed ID: 38490014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motivations for concurrent use of uppers and downers among people who access harm reduction services in British Columbia, Canada: findings from the 2019 Harm Reduction Client Survey.
    Steinberg A; Mehta A; Papamihali K; Lukac CD; Young S; Graham B; Lock K; Fleury M; Buxton JA
    BMJ Open; 2022 May; 12(5):e060447. PubMed ID: 35501101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of COVID-19 among people who use drugs: A qualitative study with harm reduction workers and people who use drugs.
    Conway FN; Samora J; Brinkley K; Jeong H; Clinton N; Claborn KR
    Harm Reduct J; 2022 Jul; 19(1):72. PubMed ID: 35780109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spatial-temporal trends in the risk of illicit drug toxicity death in British Columbia.
    Hu K; Klinkenberg B; Gan WQ; Slaunwhite AK
    BMC Public Health; 2022 Nov; 22(1):2121. PubMed ID: 36401244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Policing space in the overdose crisis: A rapid ethnographic study of the impact of law enforcement practices on the effectiveness of overdose prevention sites.
    Collins AB; Boyd J; Mayer S; Fowler A; Kennedy MC; Bluthenthal RN; Kerr T; McNeil R
    Int J Drug Policy; 2019 Nov; 73():199-207. PubMed ID: 31542327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of overdose and non-overdose mortality among people living with HIV amidst the illicit drug toxicity crisis in British Columbia.
    Yazdani K; Dhillon N; Tung A; Ye M; Trigg J; Stanley C; Ni Gusti Ayu N; McLinden T; Lima VD; Barrios R; Hogg R; Montaner JSG; Salters K
    AIDS Care; 2024 Feb; 36(2):263-271. PubMed ID: 37094365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Supporting Self-isolation for COVID-19 With "Risk Mitigation" Prescribing and Housing Supports for People Who Use Drugs: A Case Report.
    Hong RH; Brar R; Fairbairn N
    J Addict Med; 2022 Sep-Oct 01; 16(5):592-594. PubMed ID: 35149612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 months.
    Bennett AS; Townsend T; Elliott L
    Int J Drug Policy; 2022 Mar; 101():103554. PubMed ID: 34911010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feeling safer: effectiveness, feasibility, and acceptability of continuous pulse oximetry for people who smoke opioids at overdose prevention services in British Columbia, Canada.
    Moe J; Chavez T; Marr C; Cameron F; Feldman-Kiss D; Wang YE; Xavier JC; Mamdani Z; Purssell RA; Salmon A; Buxton JA
    Harm Reduct J; 2024 Feb; 21(1):45. PubMed ID: 38378610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of the COVID-19 pandemic on illicit drug supply, drug-related behaviour of people who use drugs and provision of drug related services in Georgia: results of a mixed methods prospective cohort study.
    Otiashvili D; Mgebrishvili T; Beselia A; Vardanashvili I; Dumchev K; Kiriazova T; Kirtadze I
    Harm Reduct J; 2022 Mar; 19(1):25. PubMed ID: 35264181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring trauma and wellbeing of people who use drugs after witnessing overdose: A qualitative study.
    Song M; Desai IK; Meyer A; Shah H; Saloner B; Sherman SG; Allen ST; Tomko C; Schneider KE; Krawczyk N; Whaley S; Churchill J; Harris SJ
    Int J Drug Policy; 2023 Dec; 122():104239. PubMed ID: 37890394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone.
    Perri M; Kaminski N; Bonn M; Kolla G; Guta A; Bayoumi AM; Challacombe L; Gagnon M; Touesnard N; McDougall P; Strike C
    Harm Reduct J; 2021 Aug; 18(1):85. PubMed ID: 34353323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experiences of people with opioid use disorder during the COVID-19 pandemic: A qualitative study.
    Galarneau LR; Hilburt J; O'Neill ZR; Buxton JA; Scheuermeyer FX; Dong K; Kaczorowski J; Orkin AM; Barbic SP; Bath M; Moe J; Miles I; Tobin D; Grier S; Garrod E; Kestler A
    PLoS One; 2021; 16(7):e0255396. PubMed ID: 34324589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada.
    Moshkforoush M; DeBeck K; Brar R; Fairbairn N; Cui Z; Milloy MJ; Buxton J; Oldenburger T; McLellan W; Kendall P; Sedgemore K; Wilson D; Kerr T; Hayashi K
    Harm Reduct J; 2022 May; 19(1):50. PubMed ID: 35614440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overdose deaths and the COVID-19 pandemic in British Columbia, Canada.
    Palis H; Bélair MA; Hu K; Tu A; Buxton J; Slaunwhite A
    Drug Alcohol Rev; 2022 May; 41(4):912-917. PubMed ID: 34908203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a toronto COVID-19 isolation and recovery site.
    Kolla G; Tarannum CN; Fajber K; Worku F; Norris K; Long C; Fagundes R; Rucchetto A; Hannan E; Kikot R; Klaiman M; Firestone M; Bayoumi A; Laurence G; Hayman K
    Harm Reduct J; 2024 Jan; 21(1):17. PubMed ID: 38243267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey.
    Lukac CD; Steinberg A; Papamihali K; Mehta A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Apr; 102():103602. PubMed ID: 35124412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.